Skip to main content
Journal cover image

Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.

Publication ,  Journal Article
Kao, DP; Davis, G; Aleong, R; O'Connor, CM; Fiuzat, M; Carson, PE; Anand, IS; Plehn, JF; Gottlieb, SS; Silver, MA; Lindenfeld, J; Miller, AB ...
Published in: Eur J Heart Fail
March 2013

AIMS: There is little evidence of beta-blocker treatment benefit in patients with heart failure and reduced left ventricular ejection fraction (HFREF) and atrial fibrillation (AF). We investigated the effects of bucindolol in HFREF patients with AF enrolled in the Beta-blocker Evaluation of Survival Trial (BEST). METHODS AND RESULTS: A post-hoc analysis of patients in BEST with and without AF was performed to estimate the effect of bucindolol on mortality and hospitalization. Patients were also evaluated for treatment effects on heart rate and the influence of beta1-adrenergic receptor position 389 (β(1)389) arginine (Arg) vs. glycine (Gly) genotypes. In the 303/2708 patients in AF, patients receiving bucindolol were more likely to achieve a resting heart rate ≤ 80 b.p.m. at 3 months (P < 0.005) in the absence of treatment-limiting bradycardia. In AF patients and sinus rhythm (SR) patients who achieved a resting heart rate ≤ 80 b.p.m., there were beneficial treatment effects on cardiovascular mortality/cardiovascular hospitalization [hazard ratio (HR) 0.61, P = 0.025, and 0.79, P = 0.002]. Without achieving a resting heart rate ≤ 80 b.p.m., there were no treatment effects on events in either group. β(1)389-Arg/Arg AF patients had nominally significant reductions in all-cause mortality/HF hospitalization and cardiovascular mortality/hospitalization with bucindolol (HR 0.23, P = 0.037 and 0.28, P = 0.039), whereas Gly carriers did not. There was no evidence of diminished heart rate response in β(1)389-Arg homozygotes. CONCLUSION: In HFREF patients with AF, bucindolol was associated with reductions in composite HF endpoints in those who achieved a resting heart rate ≤ 80 b.p.m. and nominally in those with the β(1)389-Arg homozygous genotype.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

March 2013

Volume

15

Issue

3

Start / End Page

324 / 333

Location

England

Related Subject Headings

  • Treatment Outcome
  • Retrospective Studies
  • Receptors, Adrenergic, beta-1
  • Proportional Hazards Models
  • Propanolamines
  • Polymorphism, Single Nucleotide
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kao, D. P., Davis, G., Aleong, R., O’Connor, C. M., Fiuzat, M., Carson, P. E., … Bristow, M. R. (2013). Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail, 15(3), 324–333. https://doi.org/10.1093/eurjhf/hfs181
Kao, David P., Gordon Davis, Ryan Aleong, Christopher M. O’Connor, Mona Fiuzat, Peter E. Carson, Inder S. Anand, et al. “Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.Eur J Heart Fail 15, no. 3 (March 2013): 324–33. https://doi.org/10.1093/eurjhf/hfs181.
Kao DP, Davis G, Aleong R, O’Connor CM, Fiuzat M, Carson PE, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar;15(3):324–33.
Kao, David P., et al. “Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.Eur J Heart Fail, vol. 15, no. 3, Mar. 2013, pp. 324–33. Pubmed, doi:10.1093/eurjhf/hfs181.
Kao DP, Davis G, Aleong R, O’Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar;15(3):324–333.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

March 2013

Volume

15

Issue

3

Start / End Page

324 / 333

Location

England

Related Subject Headings

  • Treatment Outcome
  • Retrospective Studies
  • Receptors, Adrenergic, beta-1
  • Proportional Hazards Models
  • Propanolamines
  • Polymorphism, Single Nucleotide
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Humans